![nova development corporation nova development corporation](https://images.squarespace-cdn.com/content/v1/55b39164e4b059e43b20d9d6/1550768010842-WSWZBY983NY20TJXSCYD/2015-10-23+15.47.23.jpg)
![nova development corporation nova development corporation](https://i0.wp.com/welshpiper.com/wp-content/uploads/2019/11/lowfantasypopPDF.png)
Additionally, Trulieve will hold its first event at the Carolyn Harris Performing Arts Center, Adel.Īccording to Bailey, a resident and native of Georgia, he is excited to meet experts and teach people the medical benefits of cannabis. Champ Bailey will moderate the eventĬhamp Bailey, a football Hall of Famer and the chief diversity officer at Trulieve Georgia, will moderate the event. It will cover topics like expungement, agricultural, economic, and medical opportunities in the cannabis industry. The tour aims to meet with local leaders and exchange ideas. Trulieve Cannabis Corp (OTCMKTS: TCNNF) will host a Listening and Education Tour. NOVA will equally establish a strategic relationship with leading institutions on serotonin research with a collaborative clinical setting to enroll ASD subjects in the Observational Study and potential FDA phase2A trial. Also, through a joint venture with Mycrodose Therapeutics, the company plans to create a transdermal psilocybin patch. In 2022 the company is looking to complete the human dose administration formula for Phase 2A human IND application. NOVA planning IND submission in 2022 for psilocybin The ODD will offer the NOVA market exclusivity and substantial financial benefits in the US and EU, including the possibility of accelerating the clinical development program. Four preclinical autism spectrum disorder models demonstrated the efficacy and safety of the company’s novel synthetics non-GMP psilocybin.Īlso, the company received Orphan Drug Designation from EMA and US FDA for psilocybin in the treatment of FXS. The company’s ownership of the Drug Master File will be used in drug regulatory submissions. In 2021 they accomplished the production process for non-GMP more than 98% purity psilocybin through a proprietary manufacturing agreement. I personally look forward to reporting to our shareholders this year that our clinical studies have achieved positive clinical results and that NOVA is on its way to potential drug approval and commercial sales.” Rascan added, “NOVA has laid the necessary groundwork to quickly move in 2022 to submit applications to the regulatory agencies in the U.S., Canada, and Europe for phase 2A clinical studies of psilocybin in fragile X syndrome (FXS), a rare disease with unmet medical needs. We, despite being a small drug biotech company, have achieved tremendous progress last year in our psilocybin research and drug development program, as well as established new partnerships that will help accelerate our efforts and guide us on the pathway to drug approval and commercialization.” NOVA updates on 2021 milestonesĬEO & President of NOVA, Will Rascan, said, “As we enter 2022, I want to thank NOVA’s shareholders for their continued support and investment in our company. Nova Mentis Life Science Corp (OTCMKTS: NMLSF) has reviewed its 2021 pharmaceutical development milestones and highlighted its planned 2022 initiatives toward drug approvals and commercialization.